Elsevier

Clinical Therapeutics

Volume 32, Issue 8, August 2010, Pages 1479-1495
Clinical Therapeutics

Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands

https://doi.org/10.1016/j.clinthera.2010.07.017Get rights and content

Abstract

Background: Pertussis is a highly contagious respiratory disease. Despite a high rate of vaccine coverage through the Dutch national immunization program, the incidence of pertussis remains high in the Netherlands and the risk of infection continues. Because pertussis is most severe in unimmunized infants and infants who have only received some of the recommended doses, new pertussis immunization strategies should be considered to protect this vulnerable population.

Objective: This study was designed to estimate the cost-effectiveness of 3 new immunization strategies for possible addition to the current Dutch national immunization program: immunization of the infant at birth, immunization of the parents immediately after birth of the child (cocooning), and maternal immunization during the third trimester of pregnancy.

Methods: A literature search was performed in the PubMed database for articles published in English, German, and Dutch using the following terms: pertussis, whooping cough, vaccination strategies, maternal immunization, cocooning, at birth, vaccine efficacy, mortality, underreporting, prevalence, incidence, and cost-effectiveness. A decision-tree model was developed for this analysis, and data on pertussis morbidity and costs were collected consistently for different age groups (infants <1 year of age and adults 25 to 34 years of age). The size of the infant cohort was set at 200,000 to approximate previous Dutch birth cohorts. The size of the adult cohort was set at 401,380 parents for the cocooning strategy and 201,380 mothers for the maternal immunization strategy. Health benefits (quality-adjusted life-years [QALYs]) and costs were estimated in both cohorts for each of the 3 immunization strate- gies. Incremental cost-effectiveness ratios were calculated from both a payer's and a societal perspective. The robustness of the results was determined through sensitivity analysis.

Results: In the base-case analysis, cocooning and maternal immunization were found to be effective in reducing the incidence of pertussis among infants (123 and 174 infant cases were expected to be prevented, respectively). Furthermore, cocooning and maternal immunization were estimated to be cost-effective from a payer's perspective (€4600 [US $6400]/QALY and €3500 [$4900]/QALY, respectively) and even cost-saving from a societal perspective (savings of up to €7200 [$10,100] and €5000 [$7000], respectively). Sensitivity analyses revealed that favorable cost-effectiveness was generally robust. In the sensitivity analysis, the cost-effectiveness of cocooning and maternal immunization was mostly sensitive for changes in assumptions on underreporting (200-fold increase in reported number of symptomatic cases) of pertussis disease and infection. With no underreporting, the ICER was estimated at €211,900 ($296,700)/QALY for cocooning and €81,600 ($114,200)/QALY for maternal immunization from a payer's perspective. However, even at much lower levels of underreporting (20- to 30-fold increase in incidence), cost-effectiveness remained favorable. The cost-effectiveness of the third strategy, at-birth immunization, was highly unfavorable (€329,900 [$461,900]/QALY from a payer's perspective and €330,100 [$462,100]/ QALY from a societal perspective).

Conclusions: This study estimated that the addition of cocooning or maternal immunization to the current Dutch national immunization program likely would be cost-effective or even cost-saving. These estimates were mainly due to reduction in the number of cases among parents, which are likely to be mild and therefore would largely remain unreported. Immunization at birth was not a cost-effective strategy. Cocooning was the most expensive intervention to implement; however, it resulted in the highest number of QALYs gained (mainly in adults). Maternal immunization would offer better protection of infants, due to maternally acquired antibodies.

References (68)

  • ClinicalTrials.gov

  • EL Anderson

    Prevention of pertussis

    Semin Respir Infect.

    (1989)
  • E Rothstein et al.

    Health burden of pertussis in adolescents and adults

    Pediatr Infect Dis J.

    (2005)
  • N Wood et al.

    Pertussis in infants: Preventing deaths and hospitalisations in the very young

    J Paediatr Child Health.

    (2008)
  • KD Forsyth et al.

    New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative

    Clin Infect Dis.

    (2004)
  • SS Long et al.

    Widespread silent transmission of pertussis in families: Antibody correlates of infection and symptomatology

    J Infect Dis.

    (1990)
  • SC de Greeff et al.

    Pertussis disease burden in the household: How to protect young infants

    Clin Infect Dis.

    (2010)
  • PN Baptista et al.

    Source of infection in household transmission of culture-confirmed pertussis in Brazil

    Pediatr Infect Dis J.

    (2005)
  • KM Bisgard et al.

    Infant pertussis: Who was the source?

    Pediatr Infect Dis J.

    (2004)
  • SA Halperin et al.

    Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: Report of the Immunization Monitoring Program-Active (IMPACT)

    Clin Infect Dis.

    (1999)
  • IH Loo et al.

    Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines

    Microbiology.

    (2002)
  • SC de Greeff et al.

    Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands

    Pediatr Infect Dis J.

    (2008)
  • SC De Greeff et al.

    Seasonal patterns in time series of pertussis

    Epidemiol Infect.

    (2009)
  • SC de Greeff et al.

    Pertussis in the Netherlands [in Dutch]

    Ned Tijdschr Geneeskd.

    (2010)
  • AM Wendelboe et al.

    Duration of immunity against pertussis after natural infection or vaccination

    Pediatr Infect Dis J.

    (2005)
  • J Schellekens et al.

    Pertussis sources of infection and routes of transmission in the vaccination era

    Pediatr Infect Dis J.

    (2005)
  • JI Ward et al.

    Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT

    Clin Infect Dis.

    (2006)
  • JI Ward et al.

    Efficacy of an acellular pertussis vaccine among adolescents and adults

    N Engl J Med.

    (2005)
  • N Wood et al.

    Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age

    Pediatr Infect Dis J.

    (2010)
  • M Knuf et al.

    Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

    J Pediatr.

    (2008)
  • NB Halasa et al.

    Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine

    J Pediatr.

    (2008)
  • F Kowalzik et al.

    Prospective multinational study of pertussis infection in hospitalized infants and their household contacts

    Pediatr Infect Dis J.

    (2007)
  • AM Wendelboe et al.

    Transmission of Bordetella pertussis to young infants

    Pediatr Infect Dis J.

    (2007)
  • Cited by (54)

    • Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update

      2018, Vaccine
      Citation Excerpt :

      An affordable ap vaccine for pregnant women would substantially reduce infant disease burden. Maternal immunization with ap-containing vaccines has been reported to be cost-effective in many studies [42–44] (see Table 3). wP vaccines are effective, despite being more reactogenic than aP vaccines and requiring more quality control.

    • Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil

      2016, Vaccine
      Citation Excerpt :

      Estimates of pertussis incidence used in our base case were based on confirmed cases reported to SINAN. We did not apply any correction to SINAN figures, assuming surveillance had adequate sensitivity to detect cases in infants, an assumption also made by other authors [26]. However, underreporting may occur.

    View all citing articles on Scopus

    Presented in part at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, October 24–27, 2009, in Paris, France.

    View full text